<!DOCTYPE html>
<!-- This site was created with Wowchemy. https://www.wowchemy.com -->
<!-- Last Published: October 13, 2022 --><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.7.0 for Hugo" />
  

  
  












  
  










  







  
  
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
  

  
  
  
    
      
      <link rel="preload" as="style" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap">
      <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Montserrat:wght@400;700&family=Roboto+Mono&family=Roboto:wght@400;700&display=swap" media="print" onload="this.media='all'">
    
  

  
  

  
  
    
    <script src="/js/mathjax-config.js"></script>
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.16f785cdb553c8c4431db6775122af35.css" media="print" onload="this.media='all'">

  
  
  
    
    
      <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.2/css/academicons.min.css" integrity="sha512-KlJCpRsLf+KKu2VQa5vmRuClRFjxc5lXO03ixZt82HZUk41+1I0bD8KBSA0fY290ayMfWYI9udIqeOWSu1/uZg==" crossorigin="anonymous" media="print" onload="this.media='all'">
    

    
    
    
    
      
      
    
    
    

    
    
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.e5d7adca760216d3b7e28ea434e81f6f.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  


























  
  
  






  <meta name="author" content="Alessio Crippa" />





  

<meta name="description" content="Objective: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. Methods: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. Results: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. Conclusions: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau." />



<link rel="alternate" hreflang="en-us" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2020-04_dose-response_meta-a/" />
<link rel="canonical" href="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2020-04_dose-response_meta-a/" />



  <link rel="manifest" href="/manifest.webmanifest" />



<link rel="icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png" />
<link rel="apple-touch-icon" type="image/png" href="/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_180x180_fill_lanczos_center_3.png" />

<meta name="theme-color" content="#1565c0" />










  
  






<meta property="twitter:card" content="summary" />

  <meta property="twitter:site" content="@wowchemy" />
  <meta property="twitter:creator" content="@wowchemy" />
<meta property="twitter:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" />
<meta property="og:site_name" content="Alessio Crippa" />
<meta property="og:url" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2020-04_dose-response_meta-a/" />
<meta property="og:title" content="Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia | Alessio Crippa" />
<meta property="og:description" content="Objective: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. Methods: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. Results: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. Conclusions: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau." /><meta property="og:image" content="https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />

  
    <meta
      property="article:published_time"
      content="2020-04-01T00:00:00&#43;00:00"
    />
  
  
    <meta property="article:modified_time" content="2020-04-01T00:00:00&#43;00:00">
  






    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/publication/2020-04_dose-response_meta-a/"
  },
  "headline": "Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia",
  
  "datePublished": "2020-04-01T00:00:00Z",
  "dateModified": "2020-04-01T00:00:00Z",
  
  "author": {
    "@type": "Person",
    "name": "Stefan Leucht"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Alessio Crippa",
    "logo": {
      "@type": "ImageObject",
      "url": "https://6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app/media/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Objective: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. Methods: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. Results: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. Conclusions: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau."
}
</script>

  

  




  
  
  

  
  

  


  
  <title>Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia | Alessio Crippa</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   " data-wc-page-id="1f9b6bd1e45f9ac53b42152be8f1b751" >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.ec9d49ca50e4b80bdb08f0417a28ed84.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header header--fixed">
    












<header>
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">Alessio Crippa</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#about"><span>Home</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#projects"><span>Projects</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#publications"><span>Publications</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#talks"><span>Talks</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#teaching"><span>Teaching</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#software"><span>Software</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#webapp"><span>WebApp</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
              
              
              
                
              
              
            
          

          <li class="nav-item">
            <a class="nav-link " href="/#contact"><span>Contact</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        
          
            
            <li class="nav-item d-none d-lg-inline-flex">
              <a class="nav-link" href="https://twitter.com/AlessioCrippa" data-toggle="tooltip" data-placement="bottom" title="Follow me on Twitter" target="_blank" rel="noopener" aria-label="Follow me on Twitter">
                <i class="fab fa-twitter" aria-hidden="true"></i>
              </a>
            </li>
          
        

        
        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        
        <li class="nav-item dropdown theme-dropdown">
          <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
            <i class="fas fa-moon" aria-hidden="true"></i>
          </a>
          <div class="dropdown-menu">
            <a href="#" class="dropdown-item js-set-theme-light">
              <span>Light</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-dark">
              <span>Dark</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-auto">
              <span>Automatic</span>
            </a>
          </div>
        </li>
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    








<div class="pub">

  













  

  
  
  
<div class="article-container pt-3">
  <h1>Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  <span >
      Stefan Leucht</span>, <span >
      Alessio Crippa</span>, <span >
      Spyridon Siafis</span>, <span >
      Maxine X. Patel</span>, <span >
      Nicola Orsini</span>, <span >
      John M. Davis</span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    April, 2020
  </span>
  

  

  

  
  
  
  

  
  

</div>

    




<div class="btn-links mb-3">
  
  








  
















  
  
    
  
<a class="btn btn-outline-primary btn-page-header" href="https://ajp.psychiatryonline.org/doi/full/10.1176/appi.ajp.2019.19010034" target="_blank" rel="noopener">
  Source Document
</a>




</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Objective: The dose-response relationships of antipsychotic drugs for schizophrenia are not well defined, but such information would be important for decision making by clinicians. The authors sought to fill this gap by conducting dose-response meta-analyses. Methods: A search of multiple electronic databases (through November 2018) was conducted for all placebo-controlled dose-finding studies for 20 second-generation antipsychotic drugs and haloperidol (oral and long-acting injectable, LAI) in people with acute schizophrenia symptoms. Dose-response curves were constructed with random-effects dose-response meta-analyses and a spline model. The outcome measure was total score reduction from baseline on the Positive and Negative Syndrome Scale or the Brief Psychiatric Rating Scale. The authors identified 95% effective doses, explored whether higher or lower doses than the currently licensed ones might be more appropriate, and derived dose equivalencies from the 95% effective doses. Results: Sixty-eight studies met the inclusion criteria. The 95% effective doses and the doses equivalent to 1 mg of oral risperidone, respectively, were as follows: amisulpride for patients with positive symptoms, 537 mg/day and 85.8 mg; aripiprazole, 11.5 mg/day and 1.8 mg; aripiprazole LAI (lauroxil), 463 mg every 4 weeks and 264 mg; asenapine, 15.0 mg/day and 2.4 mg; brexpiprazole, 3.36 mg/day and 0.54 mg; haloperidol, 6.3 mg/day and 1.01 mg; iloperidone, 20.13 mg/day and 3.2 mg; lurasidone, 147 mg/day and 23.5 mg; olanzapine, 15.2 mg/day and 2.4 mg; olanzapine LAI, 277 mg every 2 weeks and 3.2 mg; paliperidone, 13.4 mg/day and 2.1 mg; paliperidone LAI, 120 mg every 4 weeks and 1.53 mg; quetiapine, 482 mg/day and 77 mg; risperidone, 6.3 mg/day and 1 mg; risperidone LAI, 36.6 mg every 2 weeks and 0.42 mg; sertindole, 22.5 mg/day and 3.6 mg; and ziprasidone, 186 mg/day and 30 mg. For amisulpride and olanzapine, specific data for patients with predominant negative symptoms were available. The authors have made available on their web site a spreadsheet with this method and other updated methods that can be used to estimate dose equivalencies in practice. Conclusions: In chronic schizophrenia patients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9">American Journal of Psychiatry In American Psychiatric Publishing: , 177Article (4) 342&ndash;353. <a href="https://doi.org/10.1176/appi.ajp.2019.19010034" target="_blank" rel="noopener">https://doi.org/10.1176/appi.ajp.2019.19010034</a>. ISSN: 0002-953X</div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    





<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/antipsychotic-drugs/">Antipsychotic Drugs</a>
  
  <a class="badge badge-light" href="/tag/dose-response-curve/">Dose-Response Curve</a>
  
  <a class="badge badge-light" href="/tag/meta-analysis/">meta-analysis</a>
  
  <a class="badge badge-light" href="/tag/schizophrenia/">Schizophrenia</a>
  
</div>



<div class="share-box">
  <ul class="share">
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F&amp;text=Dose-Response&#43;Meta-Analysis&#43;of&#43;Antipsychotic&#43;Drugs&#43;for&#43;Acute&#43;Schizophrenia" target="_blank" rel="noopener" class="share-btn-twitter" aria-label="twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F&amp;t=Dose-Response&#43;Meta-Analysis&#43;of&#43;Antipsychotic&#43;Drugs&#43;for&#43;Acute&#43;Schizophrenia" target="_blank" rel="noopener" class="share-btn-facebook" aria-label="facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
        
      
      <li>
        <a href="mailto:?subject=Dose-Response%20Meta-Analysis%20of%20Antipsychotic%20Drugs%20for%20Acute%20Schizophrenia&amp;body=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F" target="_blank" rel="noopener" class="share-btn-email" aria-label="envelope">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F&amp;title=Dose-Response&#43;Meta-Analysis&#43;of&#43;Antipsychotic&#43;Drugs&#43;for&#43;Acute&#43;Schizophrenia" target="_blank" rel="noopener" class="share-btn-linkedin" aria-label="linkedin-in">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="whatsapp://send?text=Dose-Response&#43;Meta-Analysis&#43;of&#43;Antipsychotic&#43;Drugs&#43;for&#43;Acute&#43;Schizophrenia%20https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F" target="_blank" rel="noopener" class="share-btn-whatsapp" aria-label="whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https%3A%2F%2F6346b314635e8e77d95c6d10--luminous-stardust-9f8aab.netlify.app%2Fpublication%2F2020-04_dose-response_meta-a%2F&amp;title=Dose-Response&#43;Meta-Analysis&#43;of&#43;Antipsychotic&#43;Drugs&#43;for&#43;Acute&#43;Schizophrenia" target="_blank" rel="noopener" class="share-btn-weibo" aria-label="weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
















  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  
  
  
  
  













  
  
  

  
  
    
  
  
    
  

  

  
  <p class="powered-by copyright-license-text">
    © 2022 Me. This work is licensed under <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank">CC BY NC ND 4.0</a>
  </p>
  

  <p class="powered-by footer-license-icons">
    <a href="https://creativecommons.org/licenses/by-nc-nd/4.0" rel="noopener noreferrer" target="_blank" aria-label="Creative Commons">
      <i class="fab fa-creative-commons fa-2x" aria-hidden="true"></i>
      <i class="fab fa-creative-commons-by fa-2x" aria-hidden="true"></i>
      
        <i class="fab fa-creative-commons-nc fa-2x" aria-hidden="true"></i>
      
      
        <i class="fab fa-creative-commons-nd fa-2x" aria-hidden="true"></i>
      
    </a>
  </p>





  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  













  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.db4755770454eb63685f8de785c0a172.js" type="module"></script>









  
  


<script src="/en/js/wowchemy.min.e8ee06ba8371980ffde659871dd593b0.js"></script>







  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        
        <pre><code></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>


  <script src="/js/wowchemy-publication.68f8d7090562ca65fc6d3cb3f8f2d2cb.js" type="module"></script>


















</body>
</html>
